Tirzepatide results have impressed patients and doctors worldwide. This medication, known by the brand Mounjaro, is setting new standards in type 2 diabetes treatment and obesity. In this article, you'll discover what to expect from tirzepatide treatment.
What is Tirzepatide
Tirzepatide is a dual GLP-1 and GIP receptor agonist developed by Eli Lilly. Unlike conventional medications that only act on GLP-1, tirzepatide has a dual approach that enhances weight loss and glycemic control results.
Track the estimated level of each dose and know the right time to inject.
See it in the appTirzepatide Results for Weight Loss
Clinical Studies: Impressive Numbers
Clinical trials with tirzepatide demonstrated extraordinary results:
- Average weight loss: 15-22.5% of total body weight
- Waist circumference reduction: an average of 10-15 cm
- Weight maintenance: sustainable results for up to 2 years
Before and After: Real Transformations
Patients report significant transformations within the first 12 weeks of treatment. Weight loss is gradual and steady, which helps with long-term maintenance.
Tirzepatide Results for Diabetes Control
Besides weight loss, tirzepatide shows remarkable results in type 2 diabetes control:
- HbA1c reduction: up to 2.4% on average
- Fasting blood glucose: significant reductions by week 4
- Dyslipidemia: improvement in cholesterol and triglyceride levels
